ClinicalTrials.gg
RecruitingNCT07195682Updated Aug 11, 2026

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

A Phase 1 interventional study of BMS-986506 and Pumitamig in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
281
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.

Planned enrollment
11th of 33
281 · median 119
Started
2026
with 3 others
Phase 1
13 of 42
3 open now
Registered
39th of 42
by date

Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 11th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 in phase 1, and was the 39th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Metastatic clear cell renal cell carcinoma
  • Advanced clear cell renal cell carcinoma
  • ccRCC
  • Kidney cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed diagnosis of locally advanced or ccRCC.
  • For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
  • For part 2: Participants must have had at least one standard treatment plan that included both a /L1 inhibitor and a VEGF-TKI (either together or one after the other).
  • Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1/L1 checkpoint inhibitor and/or a VEGF-TKI).
  • Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
  • performance status of 0 to 1.

Exclusion criteria

Exclusion Criteria

  • Inability to administer and/or tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.
  • Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or ccRCC including prior treatment with HIF2a inhibitors.
  • Part 2A and Part 4: Participants who have received prior treatment with belzutifan (or another HIF2a inhibitor).
  • Part 3B and Part 4B: Participants who have received prior ipilimumab (or another containing antibody).
  • Participants who have hypoxia as defined by a pulse oximeter reading \< 92% at rest or requires intermittent or chronic supplemental oxygen.
  • Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.
  • Part 3 and Part 4: Participants with a history of Grade ≥3 immune-mediated AEs leading to discontinuation of prior immunotherapy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
281 participants (estimated)

Study arms

  • Experimental
    Part 1A BMS-986506 Monotherapy Escalation

    Drug: BMS-986506

  • Experimental
    Part 2A BMS-986506 Monotherapy Expansion

    Drug: BMS-986506

  • Experimental
    Part 2B BMS-986506 Monotherapy Expansion

    Drug: BMS-986506

  • Experimental
    Part 3A BMS-986506 + Pumitamig Combination Dose Escalation

    Drug: BMS-986506 · Drug: Pumitamig

  • Experimental
    Part 3B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Escalation

    Drug: BMS-986506 · Drug: Pumitamig · Drug: Ipilimumab

  • Experimental
    Part 4A BMS-986506 + Pumitamig Combination Dose Expansion

    Drug: BMS-986506 · Drug: Pumitamig

  • Experimental
    Part 4B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Expansion

    Drug: BMS-986506 · Drug: Pumitamig · Drug: Ipilimumab

Interventions

  • DrugBMS-986506

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: BMS-986545, BNT327, PM8002

  • Specified dose on specified days

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 2 years from first dose of BMS-986506

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to approximately 2 years from first dose of BMS-986506

  3. Number of Participants With AEs Meeting Protocol Defined Dose-limiting Toxicity (DLT) Criteria

    Time frame: Up to approximately Day 28

  4. Number of Participants With AEs Leading to Discontinuation

    Time frame: Up to approximately 2 years from first dose of BMS-986506

  5. Number of Participants With AEs Leading to Deaths as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0

    Time frame: Up to approximately 2 years from first dose of BMS-986506

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of BMS-986506

    Time frame: Up to approximately Day 85

  2. Time of Maximum Observed Plasma Concentration (Tmax) of BMS-986506

    Time frame: Up to approximately Day 112

  3. Area Under the Concentration-time Curve Within a Dosing Interval (AUC-TAU) of BMS-986506

    Time frame: Up to approximately Day 112

  4. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to approximately 3 years from first dose of BMS-986506

  5. Disease Control Rate (DCR) as Assessed by RECIST v1.1

    Time frame: Up to approximately 3 years from first dose of BMS-986506

  6. Duration of Response (DOR) as Assessed by RECIST v1.1

    Time frame: Up to approximately 3 years from first dose of BMS-986506

  7. Time to Response (TTR) as Assessed by RECIST v1.1

    Time frame: Up to approximately 3 years from first dose of BMS-986506

07

Study locations

9 of 11 sites recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Stephanie Berg, Site 0006 · Contact617-632-4932
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Martin Voss, Site 0029 · Contact646-888-4721
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • Elizabeth Plimack, Site 0002 · Contact215-728-3889
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Benjamin Garmezy, Site 0026 · Contact713-444-7804
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Amita Patnaik, Site 0001 · Contact210-593-5250
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
    • Daniel Heng, Site 0021 · Contact4035213166
  • Gustave Roussy
    Villejuif, Val-de-Marne 94800, France
    Recruiting
    • Christophe Massard, Site 0008 · Contact+33142114211
  • Local Institution - 0031
    Roma, 00168, Italy
    Not yet recruiting
    • Site 0031 · Contact
  • Local Institution - 0033
    Verona, 37134, Italy
    Not yet recruiting
    • Site 0033 · Contact
  • Hospital Universitario Reina Sofia
    Córdoba, Andalusia 14004, Spain
    Recruiting
    • MARIA JOSE MENDEZ VIDAL, Site 0015 · Contact+34957011448
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Cristina Suarez Rodriguez, Site 0018 · Contact349327460004350
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2030, 51 months after the start.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 51 months is close to that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Sep 29, 2025
StartActual
Jan 15, 2026
Primary completionEst.
May 3, 2030
CompletionEst.
Apr 3, 2031
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07195682
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Jan 15, 2026
Primary completion
May 3, 2030 (estimated)
Completion
Apr 3, 2031 (estimated)
Last update
Aug 11, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion